Drug Trial Radar · NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
626
Actual
Start
Apr 1, 2024
Primary completion
Sep 24, 2025
Study completion Nov 6, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.
Conditions
- Chronic Kidney Disease
- Type 2 Diabetes
- Obesity
Interventions
CagrilintideDrug
Participants will receive Cagrilintide subcutaneously.
SemaglutideDrug
Participants will receive semaglutide subcutaneously.
PlaceboDrug
Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in urinary albumin-to-creatinine ratio (UACR)Time frame: From baseline (week 0) to end of treatment (week 26)
Locations
129 sites in 13 countries. Site status is shown where the registry gives one.
John Muir Physicians Network
Concord, California
Valley Research
Fresno, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
North America Research Institute
San Dimas, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Northeast Research Institute
Fleming Island, Florida
Life Spring Research Foundation LLC
Miami, Florida
Advent Health Translational Research Institute
Orlando, Florida
Velocity Clin. Res Valparaiso
Valparaiso, Indiana
Elite Research Center
Flint, Michigan
Univ. of Nebraska Medical Center_Omaha
Omaha, Nebraska
Albany Medical College
Albany, New York
NYU Langone Nephrology Associates
Mineola, New York
New York University Grossman School of Medicine
New York, New York
Southgate Medical Group, LLP
West Seneca, New York
Carteret Medical Group
Morehead City, North Carolina
Eastern Nephrology Associates, PLLC
New Bern, North Carolina
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina
Ohio- Advanced Medical Research
Maumee, Ohio
Heritage Valley Multispeciality Group Inc
Beaver, Pennsylvania
Main Street Physician's Care
Little River, South Carolina
Osvaldo A. Brusco MD
Corpus Christi, Texas
Southwest Houston Research Ltd
Houston, Texas
Clinical Advancement Center
San Antonio, Texas
Clinical Investigation Specialists Inc, Kenosha
Kenosha, Wisconsin
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
Buenos Aires, Argentina
Centro Médico Privado San Vicente Diabetes
Córdoba, Argentina
Mautalen Salud e investigación
CABA, Buenos Aires, Argentina
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Fundación CESIM
Santa Rosa, La Pampa Province, Argentina
Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos
São Paulo, Brazil
Instituto Pró-Renal Brasil
Curitiba, Paraná, Brazil
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
Porto Alegre, Rio Grande do Sul, Brazil
CPCLIN - Centro de Pesquisas Clínicas
São Paulo, São Paulo, Brazil
Centricity Research Calgary Endocrinology
Calgary, Alberta, Canada
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Centricity Research Vaughn Endocrinology
Concord, Ontario, Canada
Centricity Research Etobicoke Endocrinology
Etobicoke, Ontario, Canada
Hamilton Medical Research Group
Hamilton, Ontario, Canada
Bluewater Clin Res Group Inc
Sarnia, Ontario, Canada
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.